| Indications | In-the-catalogue | Out-the-catalogue | d（logHR） | 95%CI | P |
| Non small cell lung cancer | Afatinib dimaleate | Nabuliumab | 0.24 | -0.01，0.51 | 0.061 |
| Dacotinib | 0.01 | -0.87，0.90 | 0.976 | ||
| Duvalizumab | -0.04 | -0.26，0.20 | 0.727 | ||
| Ometinib | 0.68 | 0.49，0.89 | < 0.001 | ||
| Arotinib hydrochloride | Nabuliumab | -0.86 | -1.13，-0.59 | < 0.001 | |
| Dacotinib | -1.09 | -1.97，-0.20 | 0.016 | ||
| Duvalizumab | -1.14 | -1.38，-0.90 | < 0.001 | ||
| Ometinib | -0.42 | -0.63，-0.21 | < 0.001 | ||
| Seretinib | Nabuliumab | 0.44 | 0.18，0.71 | 0.001 | |
| Dacotinib | 0.22 | -0.66，1.10 | 0.628 | ||
| Duvalizumab | 0.17 | -0.07，0.40 | 0.161 | ||
| Ometinib | 0.88 | 0.68，1.08 | < 0.001 | ||
| Breast cancer | Pyrrolidine maleate | Piperacillin | 0.51 | 0.24，0.78 | < 0.001 |
| Alibrin | 0.21 | -0.54，0.97 | 0.577 | ||
| Enmettrastuzumab | 0.33 | -0.04，0.71 | 0.083 | ||
| Naratinib | 0.47 | -0.31，1.25 | 0.239 | ||
| Pertuzumab | Piperacillin | 0.35 | 0.08，0.62 | < 0.001 | |
| Alibrin | 0.05 | -0.70，0.81 | 0.882 | ||
| Enmettrastuzumab | 0.17 | -0.20，0.55 | 0.268 | ||
| Naratinib | 0.31 | -0.47，1.09 | 0.419 | ||
| Melanoma | Vimofini | Pabolizumab | -0.25 | -0.72，0.23 | 0.307 |
| Darafinil mesylate | 0.34 | -0.23，0.91 | 0.242 | ||
| Trimetinib | 0.62 | 0.10，1.14 | 0.020 | ||
| Multiple myeloma | Isazomib citrate | Daretouximab | 0.14 | -0.23，0.51 | 0.460 |
| Prostatic cancer | Nzalutamide | Apatamide | 0.07 | 0.02，0.12 | 0.005 |
| Rheumatoid arthritis | Tofacitinib citrate | Peselizumab | -0.33 | -0.90，0.24 | 0.262 |
| Abasipu | 0.14 | -0.37，0.65 | 0.589 | ||
| Gollimumab | Peselizumab | 1.01 | 0.43，1.59 | 0.001 | |
| Abasipu | 1.48 | 0.95，2.00 | < 0.001 | ||
| Barretinib | Peselizumab | -0.60 | -1.13，-0.07 | 0.026 | |
| Abasipu | -0.13 | -0.60，0.33 | 0.570 |
